The drug, known as Breo Ellipta in the US, has already disappointed in one pivotal study. The Summit trial, published 12 months ago, showed the drug failed to cut the risk of death in COPD ...

Do not initiate in rapidly or acutely deteriorating COPD or asthma. Not for use with other long-acting β 2-agonists. Do not exceed recommended dose. Prescribe a short-acting, inhaled β 2-agonist ...

which showed Trelegy was better than GSK’s already approved combinations Relvar/Breo Ellipta and Anoro Ellipta. Trelegy is also indicated to reduce exacerbations of COPD in patients with a ...